ARAV Stock Hits Multi-Year High on Solid Phase 1 Data for AVB-500
ARAV stock is hitting a multi-year high after Aravive Inc (NASDAQ:ARAV) reported positive data from a Phase 1b clinical trial evaluating its lead candidate AVB-500 in platinum-resistant ovarian cancer. Impressive Data This morning, the company ... [Read]